1. sars-cov-2 infection diagnosed during the previous 90 days. 2. last sars-cov-2 vaccine dose during the previous 30 days. 3. no significant limitations in the subject's ability to perform all usual duties/activities (i.e., grades 0, 1 or 2 in pcfs scale). 4. medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload, among others). 5. pregnant or breastfeeding women. 6. contraindications for therapeutic pe: non-availability of an adequate peripheral venous catheter, hemodynamic instability, septicemia, known allergy to fresh frozen plasma or replacement colloid/albumin, known allergy to heparin. 7. current or planned hospital admission for any cause during the study follow-up. 8. inability to consent and/or comply with study requirements, in the opinion of the investigator. 9. currently participating or planning to participate in any other clinical trial until day 90 of follow-up.

1. sars-cov-2 infection diagnosed during the previous 90 days. 2. last sars-cov-2 vaccine dose during the previous 30 days. 3. no significant limitations in the subject's ability to perform all usual duties/activities (i.e., grades 0, 1 or 2 in pcfs scale). 4. medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload, among others). 5. pregnant or breastfeeding women. 6. contraindications for therapeutic pe: non-availability of an adequate peripheral venous catheter, hemodynamic instability, septicemia, known allergy to fresh frozen plasma or replacement colloid/albumin, known allergy to heparin. 7. current or planned hospital admission for any cause during the study follow-up. 8. inability to consent and/or comply with study requirements, in the opinion of the investigator. 9. currently participating or planning to participate in any other clinical trial until day 90 of follow-up.

sars-cov-2 infection diagnosed during the previous 90 days. last sars-cov-2 vaccine dose during the previous 30 days. no significant limitations in the subject's ability to perform all usual duties/activities (i.e., grades 0, 1 or 2 in pcfs scale). medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload, among others). pregnant or breastfeeding women. contraindications for therapeutic pe: non-availability of an adequate peripheral venous catheter, hemodynamic instability, septicemia, known allergy to fresh frozen plasma or replacement colloid/albumin, known allergy to heparin. current or planned hospital admission for any cause during the study follow-up. inability to consent and/or comply with study requirements, in the opinion of the investigator. currently participating or planning to participate in any other clinical trial until day 90 of follow-up.

sars-cov-2 infection diagnosed during the previous 90 days. last sars-cov-2 vaccine dose during the previous 30 days. no significant limitations in the subject's ability to perform all usual duties/activities (i.e., grades 0, 1 or 2 in pcfs scale). medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload, among others). pregnant or breastfeeding women. contraindications for therapeutic pe: non-availability of an adequate peripheral venous catheter, hemodynamic instability, septicemia, known allergy to fresh frozen plasma or replacement colloid/albumin, known allergy to heparin. current or planned hospital admission for any cause during the study follow-up. inability to consent and/or comply with study requirements, in the opinion of the investigator. currently participating or planning to participate in any other clinical trial until day 90 of follow-up.